Pottumarthi Prasad1, Wei Li1, Thomas Schnitzer2, Nitya Krishnan3, Deborah Burstein3
1NorthShore University HealthSystem, Evanston, IL, United States; 2Feinberg School of Medicine, Northwestern University, Chicago, IL, United States; 3Radiology, Beth Israel Deaconess Medical Center, Boston, MA, United States
Treatment of osteoarthritis remains to be symptom modification, although the concept of disease modification is currently evolving. Hylan G-F 20 has been shown to demonstrate disease modifying effects, even though it is currently approved for symptom modification. We have performed preliminary evaluation to see if dGEMRIC can detect changes in patients treated with Hylan G-F 20 in a small number of subjects. While we observed little change, we believe this may be due to the relatively advanced disease status. This is in general agreement with other published human trials using joint space width as an outcome measure.